| The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Cancer Journal 11 (8), 138, 2021 | 125 | 2021 |
| Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study M Gavriatopoulou, E Terpos, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Advances 5 (21), 4398-4405, 2021 | 44 | 2021 |
| Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance E Kastritis, F Theodorakakou, M Roussou, E Psimenou, C Gakiopoulou, ... British Journal of Haematology 193 (1), 113-118, 2021 | 30 | 2021 |
| Next generation flow cytometry for MRD detection in patients with AL amyloidosis E Kastritis, IV Kostopoulos, F Theodorakakou, D Fotiou, M Gavriatopoulou, ... Amyloid 28 (1), 19-23, 2021 | 30 | 2021 |
| Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis E Kastritis, D Fotiou, F Theodorakakou, I Dialoupi, M Migkou, M Roussou, ... Amyloid 28 (1), 3-11, 2021 | 25 | 2021 |
| Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, excluding those under anti-BCMA therapy I Ntanasis-Stathopoulos, V Karalis, M Gavriatopoulou, P Malandrakis, ... Hemasphere 6 (8), e764, 2022 | 23 | 2022 |
| Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study A Cowan, F Ferrari, SS Freeman, R Redd, H El-Khoury, J Perry, V Patel, ... The Lancet Haematology 10 (3), e203-e212, 2023 | 22 | 2023 |
| Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine M Gavriatopoulou, E Terpos, P Malandrakis, I Ntanasis‐Stathopoulos, ... British Journal of Haematology 196 (2), 356-359, 2022 | 22 | 2022 |
| Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review G Georgiopoulos, N Makris, A Laina, F Theodorakakou, A Briasoulis, ... Cardio Oncology 5 (1), 1-21, 2023 | 19 | 2023 |
| Upfront daratumumab with lenalidomide and dexamethasone for POEMS syndrome M Gavriatopoulou, I Ntanasis-Stathopoulos, D Fotiou, M Migkou, ... HemaSphere 4 (3), e381, 2020 | 19 | 2020 |
| Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications E Kastritis, M Migkou, D Dalampira, M Gavriatopoulou, D Fotiou, ... American Journal of Hematology 97 (9), 1142-1149, 2022 | 18 | 2022 |
| Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European Myeloma Network E Kastritis, MC Minnema, MA Dimopoulos, G Merlini, F Theodorakakou, ... Blood 138, 2730, 2021 | 13 | 2021 |
| Biomarkers in AL amyloidosis D Fotiou, F Theodorakakou, E Kastritis International journal of molecular sciences 22 (20), 10916, 2021 | 13 | 2021 |
| Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease E Kastritis, P Rousakis, IV Kostopoulos, M Gavriatopoulou, ... Amyloid 28 (4), 259-266, 2021 | 12 | 2021 |
| Impact of daratumumab-containing induction on stem cell mobilization and collection, engraftment and hospitalization parameters among multiple myeloma patients undergoing … EE Papaiakovou, E Terpos, N Kanellias, M Migkou, M Gavriatopoulou, ... Blood 138, 3886, 2021 | 11 | 2021 |
| The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021; 11 (8): 138 E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... | 11 | |
| Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies T Bagratuni, A Markou, D Patseas, N Mavrianou-Koutsoukou, F Aktypi, ... Blood advances 6 (1), 189-199, 2022 | 10 | 2022 |
| Solid organ transplantation in amyloidosis F Theodorakakou, D Fotiou, MA Dimopoulos, E Kastritis Acta Haematologica 143 (4), 352-364, 2020 | 9 | 2020 |
| Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study E Kastritis, E Terpos, A Symeonidis, V Labropoulou, S Delimpasi, ... American journal of hematology 98 (9), E226-E229, 2023 | 7 | 2023 |
| Use of oral antivirals ritonavir-nirmatrelvir and molnupiravir in patients with multiple myeloma is associated with low rates of severe COVID-19: a single-center, prospective study V Spiliopoulou, I Ntanasis-Stathopoulos, P Malandrakis, ... Viruses 15 (3), 704, 2023 | 7 | 2023 |
